RNA binding proteins in MLL-rearranged leukemia

Tiffany M Tran; Dinesh S Rao

doi:10.1186/s40164-022-00343-5

RNA binding proteins in MLL-rearranged leukemia

Exp Hematol Oncol. 2022 Oct 28;11(1):80. doi: 10.1186/s40164-022-00343-5.

Authors

Tiffany M Tran^{1

2}, Dinesh S Rao^{3

4

5}

Affiliations

¹ Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, USA.
² Molecular, Cellular, and Integrative Physiology Interdepartmental Ph.D. Program, UCLA, Los Angeles, CA, 90095, USA.
³ Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, USA. DRao@mednet.ucla.edu.
⁴ Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, 90095, USA. DRao@mednet.ucla.edu.
⁵ Broad Stem Cell Research Center, UCLA, Los Angeles, CA, 90095, USA. DRao@mednet.ucla.edu.

Abstract

RNA binding proteins (RBPs) have recently emerged as important post-transcriptional gene expression regulators in both normal development and disease. RBPs influence the fate of mRNAs through multiple mechanisms of action such as RNA modifications, alternative splicing, and miR-mediated regulation. This complex and, often, combinatorial regulation by RBPs critically impacts the expression of oncogenic transcripts and, thus, the activation of pathways that drive oncogenesis. Here, we focus on the major features of RBPs, their mechanisms of action, and discuss the current progress in investigating the function of important RBPs in MLL-rearranged leukemia.

Keywords: Leukemia; MLL; RNA binding protein.

Publication types

Review

Abstract

Publication types

Grants and funding